Wealth Whale
4K posts
🚨 WARNING: THE NEXT 24 HOURS WILL CHANGE EVERYTHING!!
The U.S. stock market is about to repeat history.
S&P 500 is now mirroring the same pattern we saw during the dot-com bubble.
The setup is IDENTICAL.
If you hold any assets right now, you MUST know what’s coming next:
Back in 2000, markets looked unstoppable.
Momentum was strong.
Confidence was high.
And then everything broke.
Billions were erased.
Portfolios were crushed.
And the dump was brutal.
Right now, the chart is lining up almost point for point.
Same breakout.
Same overextension.
Same false sense of security.
And the warning signs are flashing.
Valuations are stretched.
Liquidity is tightening.
Volatility is waking up.
And risk is building underneath the surface.
Most investors still don’t see it.
Because at the top, everything feels normal.
That’s how every major correction starts.
Optimism peaks.
Positioning gets crowded.
And complacency takes over.
Then the reversal begins.
Fast.
And once momentum flips, there is no gradual exit.
There is only repricing.
The market does not wait.
It resets.
And when it does, it moves violently.
Right now, there are three paths ahead:
1⃣ SOFT RESET
The market cools off.
Valuations compress.
Momentum stabilizes.
2⃣ DEEP CORRECTION
Selling accelerates.
Fear returns.
Risk assets dump lower.
3⃣ FULL DOT-COM STYLE COLLAPSE
Support breaks.
Panic spreads.
Liquidity disappears.
Forced selling takes over.
That is where real damage happens.
Because when leverage unwinds, everything gets hit.
Stocks.
Crypto.
Speculative assets.
EVERYTHING.
The chart is there.
The setup is there.
And history is staring investors in the face.
Watch price action.
Watch liquidity.
Watch volatility.
Because if this pattern completes, the next move will be impossible to ignore.
And by the time everyone sees it - the market will already be lower.
I’ve spent 10 years studying markets, and I’ve called most major tops and bottoms along the way.
And I’ll call it again in 2026.
Follow me and turn notifications on before it’s too late.
Don’t become the exit liquidity.
English
🩸 CRASH:
$406,000,000,000 has been wiped out from US stock market in just 30 MINUTES.
English
Wealth Whale retweetledi
#earnings for the week of April 27, 2026
earningswhispers.com/calendar
$MSFT $AMZN $AAPL $META $SNDK $SOFI $GOOGL $HOOD $CLS $BE $VZ $STX $TER $V $WDC $UPS $COP $ENPH $CAT $APH $OPK $RDDT $QCOM $CMG $CVX $F $VLO $W $AXTI $HUM $KGC $LLY $MA $KO $RIVN $GLW $CL $RMBS $SPOT $REGN $RIOT $JKS $MDLZ $MO $MRK $MTZ $CDNS $CAR $ARE $AMGN
English
Absolutely incredible:
US oil prices are now nearing $103/barrel and have been rising at a pace of $1/hour since 6 AM ET.
This puts oil prices +12% above the low seen just ~24 hours ago as ceasefire doubts have grown.
Meanwhile, Iran's Deputy Foreign Minister announced that Iran was "on the verge" of responding to "ceasefire violations" last night, but Pakistan intervened.
Iran is also not allowing more than 15 vessels per day to pass through the Strait of Hormuz, or just ~10% of pre-war levels.
This is in sharp contrast to President Trump's claims that Iran would implement a "complete and immediate" opening of the Strait of Hormuz.
Triple digit oil prices are back in full-swing.
English
A whale has opened a $30,113,000 $BTC short with 40x leverage.
Liquidation Price: $71,941
English
Wealth Whale retweetledi
🚨NEARLY HALF OF CANCER PATIENTS TAKING IVERMECTIN + MEBENDAZOLE REPORTED CANCER DISAPPEARANCE OR TUMOR REGRESSION AFTER 6 MONTHS
84.4% EXPERIENCED CLINICAL BENEFIT
32.8% REPORTED NO EVIDENCE OF DISEASE
15.6% REPORTED TUMOR REGRESSION
36.1% REPORTED STABLE DISEASE
Our study represents the largest and most compelling clinical signal to date supporting antiparasitic therapy in cancer.
@McCulloughFund @twc_health @P_McCulloughMD @DrHarveyRisch @DrKellyVictory @jathorpmfm @drdrew @PeterGillooly @FosterCoulson
Nicolas Hulscher, MPH@NicHulscher
🚨BREAKING: Largest Real-World Study of Ivermectin + Mebendazole in Cancer Patients Shows 84.4% Clinical Benefit — Nearly HALF Report Cancer Disappearance or Tumor Regression After just 6 months, 48.4% of cancer patients taking ivermectin and mebendazole reported NO EVIDENCE OF DISEASE (32.8%) or tumor regression (15.6%), while 36.1% reported disease stabilization⬇️ We have completed the largest real-world human analysis to date evaluating ivermectin and mebendazole in cancer patients—and the results represent one of the most compelling clinical signals ever documented for repurposed anti-parasitic therapies in oncology. The groundbreaking analysis was made possible through a unique collaboration between The Wellness Company, the McCullough Foundation, and the Chairman of the President’s Cancer Panel (Dr. Harvey Risch)—uniting real-world clinical data, frontline medical experience, and high-level epidemiologic expertise to deliver urgently needed insights in oncology. This was a real-world prospective clinical program evaluation of 197 cancer patients, with 122 completing a follow-up survey at about six months (61.9% response rate). Cancer patients were prescribed compounded ivermectin–mebendazole, with each capsule containing 25 mg ivermectin and 250 mg mebendazole—most commonly taken at 1–2 capsules per day. The cohort represented a clinically relevant population, including a wide variety cancer types, with 37.1% of patients reporting actively progressing disease at baseline and many having already undergone chemotherapy, radiation, and surgery. At six months, 84.4% of cancer patients reported clinical benefit (Clinical Benefit Ratio: 84.4% [95% CI: 77.0–89.8%]): ✅ 32.8% reported no evidence of disease (95% CI: 25.1–41.5%) ✅ 15.6% reported tumor regression (95% CI: 10.2–23.0%) ✅ 36.1% reported stable disease (95% CI: 28.1–44.9%) Treatment adherence was high, with 86.9% completing the full protocol and 66.4% remaining on therapy at six months. The regimen was well tolerated, with 25.4% reporting side effects, primarily mild and gastrointestinal, and over 93% continuing treatment despite these events. Patients were treated in real-world conditions alongside concurrent therapies, including chemotherapy (27.9%), radiation (21.3%), surgery (19.7%), supplements (49.2%), and dietary modification (37.7%), supporting use as an adjunctive approach. Together, these findings represent a large, internally consistent real-world clinical signal that supports URGENT further investigation of ivermectin and mebendazole as low-toxicity, adjunctive cancer therapies. Given the strength of the signal observed here, advancing this line of investigation is no longer optional—it is necessary. This is NOT the end. We will continue advancing this work with larger datasets to further define and validate the role of anti-parasitics in cancer outcomes. The manuscript is now available as a preprint on the Zenodo research repository, operated by the European Organization for Nuclear Research, while undergoing peer review at leading oncology journals: “Real-World Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort.” @twc_health @McCulloughFund @P_McCulloughMD @DrHarveyRisch @DrKellyVictory @jathorpmfm @drdrew @PeterGillooly @FosterCoulson
English
Wealth Whale retweetledi
JUST IN: Jim Cramer says "get ready for a bad" market open.
English
Wealth Whale retweetledi
Wealth Whale retweetledi
@DefiWimar Dear Trump,
Oh please, Earth was doing just fine before you turned it into a reality show sequel. If you're heading to Mars, take your "tremendous" ego with you—maybe it'll finally have enough space. Don't forget to pack your red hat; it'll match the planet.
English
Wealth Whale retweetledi
RICHTECH ROBOTICS HAS REVEALED THEIR NEW HUMANOID ROBOT "DEX" AT @NVIDIAGTC 🚨🚨🚨 AND IT LOOKS ABSOLUTELY AMAZING. HEARING THAT THE MSAs WITH THE LARGE RETAILERS INVOLVE DEX. WE WARNED YOU. @RichtechRobots @NVIDIARobotics @NVIDIARobotics $RR #bullish #robotics #StocksToWatch
English
